Teacher Retirement System of Texas Sells 3,190 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Teacher Retirement System of Texas cut its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 14.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,459 shares of the company’s stock after selling 3,190 shares during the quarter. Teacher Retirement System of Texas’ holdings in Apellis Pharmaceuticals were worth $404,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in APLS. Avoro Capital Advisors LLC raised its stake in shares of Apellis Pharmaceuticals by 10.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company’s stock valued at $390,011,000 after purchasing an additional 1,111,111 shares during the period. Vanguard Group Inc. boosted its holdings in Apellis Pharmaceuticals by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 10,046,025 shares of the company’s stock valued at $320,569,000 after acquiring an additional 230,450 shares during the period. AQR Capital Management LLC boosted its holdings in Apellis Pharmaceuticals by 127.2% during the 4th quarter. AQR Capital Management LLC now owns 1,856,442 shares of the company’s stock valued at $59,239,000 after acquiring an additional 1,039,182 shares during the period. Geode Capital Management LLC raised its position in Apellis Pharmaceuticals by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company’s stock valued at $58,699,000 after purchasing an additional 28,426 shares during the last quarter. Finally, Deutsche Bank AG raised its position in shares of Apellis Pharmaceuticals by 1.8% in the 4th quarter. Deutsche Bank AG now owns 1,778,377 shares of the company’s stock worth $56,748,000 after acquiring an additional 30,867 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $20.04 on Friday. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $41.94. The company has a market capitalization of $2.52 billion, a PE ratio of -11.20 and a beta of 0.67. The company has a fifty day moving average of $18.19 and a two-hundred day moving average of $22.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same quarter in the previous year, the business earned ($0.54) EPS. Apellis Pharmaceuticals’s revenue for the quarter was down 3.2% on a year-over-year basis. As a group, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $18.77, for a total value of $93,850.00. Following the completion of the sale, the general counsel directly owned 133,730 shares of the company’s stock, valued at approximately $2,510,112.10. The trade was a 3.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 137,465 shares of the business’s stock in a transaction on Monday, July 14th. The shares were sold at an average price of $20.19, for a total transaction of $2,775,418.35. Following the sale, the chief executive officer directly owned 343,433 shares of the company’s stock, valued at $6,933,912.27. This represents a 28.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 144,365 shares of company stock valued at $2,907,439. Corporate insiders own 6.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on APLS. Scotiabank reduced their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating for the company in a research report on Thursday, May 8th. Needham & Company LLC lowered their target price on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Bank of America raised their price target on Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a “neutral” rating in a report on Wednesday. Cantor Fitzgerald assumed coverage on Apellis Pharmaceuticals in a report on Tuesday, April 29th. They issued an “overweight” rating and a $44.00 target price on the stock. Finally, Wells Fargo & Company boosted their price objective on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Monday, June 2nd. Nine analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $39.84.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).